Pharmaceutical

Basilea buys Spexis’ preclinical antibiotics programme for $2.3m

The acquired programme consists of antibiotics against gram-negative bacteria, including multidrug-resistant strains.

Jan 15, 2024 - 18:00
Basilea buys Spexis’ preclinical antibiotics programme for $2.3m
The acquired programme consists of antibiotics against gram-negative bacteria, including multidrug-resistant strains.
Read the original article

Tags:

Previous Article

MSD’s Keytruda wins expanded FDA combo approval in cervical cancer

Next Article

PCM Trials acquires Netherlands-based Clinical Trial Service, becoming the most ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Why I left the editorial board of the prestigious scientific journal NeuroImage — and helped start something new

Opinion: Why I left the editorial board of the prestigi...

Feb 1, 2024

Candor on gene therapy, Abiomed is warned, & BTK success in MS

Candor on gene therapy, Abiomed is warned, & BTK succes...

Oct 16, 2023

AI database to bolster research for GLP1-RAs as precision medicines

AI database to bolster research for GLP1-RAs as precisi...

May 15, 2024